- Home
- ACXP vs PPBT Comparison
ACXP vs PPBT Comparison
Compare ACXP & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- PPBT
- Stock Information
- Founded
- ACXP 2017
- PPBT 2010
- Country
- ACXP United States
- PPBT Israel
- Employees
- ACXP N/A
- PPBT N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- PPBT Health Care
- Exchange
- ACXP Nasdaq
- PPBT Nasdaq
- Market Cap
- ACXP 6.8M
- PPBT 5.5M
- IPO Year
- ACXP 2021
- PPBT N/A
- Fundamental
- Price
- ACXP $6.30
- PPBT $0.58
- Analyst Decision
- ACXP Strong Buy
- PPBT Strong Buy
- Analyst Count
- ACXP 3
- PPBT 1
- Target Price
- ACXP $143.67
- PPBT $33.00
- AVG Volume (30 Days)
- ACXP 1.6M
- PPBT 234.4K
- Earning Date
- ACXP 11-12-2025
- PPBT 11-14-2025
- Dividend Yield
- ACXP N/A
- PPBT N/A
- EPS Growth
- ACXP N/A
- PPBT N/A
- EPS
- ACXP N/A
- PPBT N/A
- Revenue
- ACXP N/A
- PPBT N/A
- Revenue This Year
- ACXP N/A
- PPBT N/A
- Revenue Next Year
- ACXP N/A
- PPBT N/A
- P/E Ratio
- ACXP N/A
- PPBT N/A
- Revenue Growth
- ACXP N/A
- PPBT N/A
- 52 Week Low
- ACXP $3.80
- PPBT $0.53
- 52 Week High
- ACXP $39.20
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- ACXP 54.01
- PPBT 29.48
- Support Level
- ACXP $6.24
- PPBT $0.56
- Resistance Level
- ACXP $6.80
- PPBT $0.61
- Average True Range (ATR)
- ACXP 0.61
- PPBT 0.03
- MACD
- ACXP -0.13
- PPBT 0.04
- Stochastic Oscillator
- ACXP 3.16
- PPBT 20.64
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.